Acute Exacerbation of COPD (AECOPD)

Definition

• The Washington Manual of Medical Therapeutics, p. 320

Causes / Triggers

Respiratory infections (viral and bacterial) and air pollution cause most exacerbations.

Diagnosis & Initial Assessment

• Respiratory failure: PaO₂ <60 mmHg or SaO₂ <90% on room air
• Acute respiratory acidosis: PaCO₂ >44 mmHg + pH <7.35
• Acute: HCO₃ rises by 1 mEq/L per 10 mmHg rise in PaCO₂
• Chronic compensation: HCO₃ rises by 3.5 mEq/L per 10 mmHg rise in PaCO₂
• Tintinalli's Emergency Medicine, p. 510; Rosen's Emergency Medicine, p. 2560-2564

Severity Classification & Disposition

• Significant increase in symptom severity
• Severe underlying COPD (FEV₁ <50%)
• Significant comorbidities
• Failure to respond to initial medical management
• Diagnostic uncertainty
• Insufficient home support

• Need for invasive mechanical ventilation
• Hemodynamic instability
• Severe dyspnea not responding to therapy
• Mental status changes
• Persistent or worsening hypoxemia, hypercapnia, or respiratory acidosis despite supplemental O₂ and NIV
• Washington Manual, p. 320

Treatment

1. Supplemental Oxygen

• Target SpO₂ of 88%-92% (PaO₂ 60-70 mmHg)
• Higher oxygen targets carry potential harm (hypercapnic drive suppression, absorption atelectasis, Haldane effect)
• Use controlled flow (e.g., Venturi mask) to titrate delivery

2. Short-Acting Bronchodilators (First-Line)

• SABAs are first-line; add short-acting anticholinergics (SAMA) if inadequate response
• Nebulizers preferred in the ED setting (patients too dyspneic for optimal MDI technique); use air-driven nebulizers rather than oxygen-driven when possible (to avoid hyperoxia)
• Continuous nebulization is NOT indicated
• Long-acting bronchodilators should be considered once the patient is stable

3. Systemic Corticosteroids

• Decrease recovery time, improve oxygenation and lung function, shorten hospital stay
• Prednisone 40 mg/day for 5 days - recommended over longer regimens
• Mechanism: inhibit cytokine expression and eosinophil apoptosis
• Recommended for all inpatients and most outpatients with exacerbation

4. Antibiotics

• Antibiotics most clearly benefit patients with sputum purulence and those requiring mechanical ventilation
• Duration: 5-7 days
• Role of CRP/PCT: PCT-guided antibiotic reduction may be appropriate in non-critically-ill patients, but in ICU patients, prompt antibiotics outweigh the need for judicious prescribing
• Avoid antibiotics in ED discharge patients without signs of infection (no clear mortality benefit)

5. Avoid Methylxanthines

• Theophylline carries risk of serious side effects - avoid initiating during acute exacerbation
• If a patient uses methylxanthines chronically, do NOT discontinue during exacerbation (risk of decompensation)

6. Noninvasive Ventilation (NIV/NPPV)

• Reduced need for intubation
• Shorter hospital and ICU length of stay
• Decreased in-hospital mortality
• Improves respiratory rate, tidal volume, minute ventilation
• Mechanisms: improved respiratory mechanics and alveolar ventilation

NIV should be initiated early along with standard medical therapy. If started late (after failure of medical treatment), the mortality and ICU benefits are lost. Early NIV in the ED is considered the standard of care for eligible patients.

• Roberts and Hedges' Clinical Procedures in Emergency, p. 231; Fishman's Pulmonary Diseases, p. 2630; Washington Manual, p. 321

7. Invasive Mechanical Ventilation

• Respiratory arrest or near-arrest
• Hemodynamic instability unresponsive to therapy
• Persistent worsening despite NIV
• Inability to protect airway

8. Thromboprophylaxis

• DVT prophylaxis should be used in all hospitalized AECOPD patients (increased thrombosis risk)

Differential Diagnosis

• Pneumothorax
• Pneumonia
• Pleural effusion
• Congestive heart failure
• Cardiac ischemia/ACS
• Pulmonary embolism
• Cardiac arrhythmia

Key ECG Findings in COPD

• P pulmonale (peaked P waves >2.5 mm in leads II, III, aVF)
• Low QRS voltage (due to hyperinflated lungs)
• Poor R-wave progression (≤3 mm in V3)
• Tachyarrhythmias in up to 35% of exacerbations (AF, atrial flutter, multifocal atrial tachycardia)
• Rosen's Emergency Medicine, p. 2555

Recent Evidence Notes

Acute Exacerbation of COPD - Harrison's Principles of Internal Medicine, 22nd Edition (2025)

Definition

Epidemiology & Natural History

• Exacerbations are a prominent feature of the natural history of COPD
• The strongest single predictor of exacerbation is a history of a previous exacerbation
• Frequency increases as airflow obstruction worsens: patients with FEV₁ <50% predicted average 1-3 episodes per year
• However, some individuals with severe airflow obstruction do not have frequent exacerbations
• Additional risk factors: current smoking, elevated pulmonary artery-to-aorta diameter ratio on chest CT, gastroesophageal reflux
• A majority of the $50 billion annual COPD-related healthcare expenditures in the US are attributable to exacerbations

Precipitating Causes

Patient Assessment

History

• Quantify degree and change in dyspnea (breathlessness during ADLs and typical activities)
• Fever, change in character of sputum (volume, purulence)
• Associated symptoms: wheezing, nausea, vomiting, diarrhea, myalgias, chills
• Frequency and severity of prior exacerbations
• The single greatest risk factor for hospitalization is a history of previous hospitalization

Physical Examination

• Degree of patient distress
• Tachycardia, tachypnea
• Use of accessory muscles
• Perioral or peripheral cyanosis
• Ability to speak in complete sentences
• Mental status
• Chest: focal findings, degree of air movement, wheezing, asymmetry (suggesting large airway obstruction or pneumothorax), paradoxical abdominal wall motion

Investigations

Criteria for Inpatient Admission

• Respiratory acidosis and hypercarbia
• New or worsening hypoxemia
• Severe underlying COPD
• Significant comorbidities (e.g., heart failure)
• Living situation not conducive to careful observation and delivery of prescribed treatment

Treatment

1. Bronchodilators

• Patients are treated with inhaled beta-agonists and muscarinic antagonists, either separately or in combination
• Frequency depends on severity of exacerbation
• Nebulized therapy is used initially (easier to administer in respiratory distress)
• Conversion to metered-dose inhalers (MDIs) is effective when accompanied by patient and staff education - has significant economic benefits and eases the transition to outpatient care

2. Antibiotics

• COPD patients are frequently colonized with potential respiratory pathogens, making it difficult to identify a specific causative organism
• Antibiotic choice should be guided by local patterns of antibiotic susceptibility and the patient's clinical condition
• Patients with moderate or severe exacerbations are usually treated with 5-7 days of antibiotics, even in the absence of data implicating a specific pathogen

3. Glucocorticoids

• In hospitalized patients: systemic glucocorticoids reduce length of stay, hasten recovery, and reduce the chance of subsequent exacerbation or relapse
• Dose: oral prednisone 40 mg (or equivalent) for 5 days
• Most common acute complication: hyperglycemia - particularly in patients with preexisting diabetes

4. Supplemental Oxygen

• Target oxygen saturation: 88-92%
• In patients with acute and chronic hypercarbia, supplemental O₂ does not reduce minute ventilation, but in some patients causes modest increases in arterial PaCO₂ - chiefly by altering ventilation-perfusion (V/Q) relationships (not primarily by suppressing hypoxic drive as previously taught)
• This should not deter practitioners from providing oxygen needed to correct hypoxemia

5. Noninvasive Positive-Pressure Ventilation (NIPPV)

• Significant reduction in mortality rate
• Reduced need for intubation
• Fewer complications of therapy
• Shorter hospital length of stay

6. Invasive Mechanical Ventilation

• Severe respiratory distress
• Hypoxemia
• Severe hypercarbia and/or acidosis despite NIPPV
• Markedly impaired mental status
• Respiratory arrest
• Hemodynamic instability
• Other complications

• Ensure sufficient expiratory time due to severe airflow obstruction
• Watch for auto-PEEP (intrinsic PEEP) - patients must generate significant additional respiratory effort to trigger a breath during demand-mode ventilation
• The mortality rate of patients requiring mechanical ventilatory support for a COPD exacerbation is in the range of 17-30% and is associated with the severity of the underlying illness

Key Harrison's Teaching Points

1. Viral infections cause >50% of AECOPD - not bacterial, as once thought
2. Acquiring a new bacterial strain (not just colonizing bacteria) drives exacerbation risk
3. PE must always be considered - its incidence is elevated during AECOPD
4. Spirometry is NOT useful in diagnosing or managing AECOPD (unlike in asthma)
5. The V/Q mismatch mechanism (not respiratory drive suppression) primarily explains CO₂ rise with O₂ therapy
6. NIPPV has a mortality benefit when initiated for respiratory acidosis - it is not just a comfort measure
7. Prior hospitalization is the single greatest risk factor for hospitalization in a new exacerbation